1. Approved the Audited Standalone and Consolidated Financial Results for the quarter and year ended 31st March, 2026 together with the Report issued by the Statutory Auditors, M/s. Krishaan ....
THEMISMED · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Themis Medicare reported a sharp decline in standalone performance for FY ended March 2026. Revenue from operations fell 15.6% to Rs. 34,223.55 lakhs from Rs. 40,551.16 lakhs in the prior year. The company posted a standalone loss before tax of Rs. 1,340.10 lakhs versus a profit of Rs. 3,376.36 lakhs in FY2025, with PAT negative at Rs. 1,418.55 lakhs vs Rs. 2,392.15 lakhs. On a consolidated basis, revenue similarly declined 15.6% but the company remained marginally profitable with PAT of Rs. 114.37 lakhs (vs Rs. 2,983.28 lakhs), supported by associate/joint venture contributions of Rs. 1,404.84 lakhs. Exceptional items included Rs. 86.53 lakhs labour code impact and Rs. 129.39 lakhs write-off of Carpo Medicals Limited (wholly owned subsidiary awaiting RBI approval for dissolution). The Board recommended a dividend of Rs. 0.50 per share (50% on face value Rs. 1). Auditors Krishaan & Co. issued clean (unmodified) opinions on both standalone and consolidated financials.
The company swung to a standalone net loss for FY2026, driven by revenue contraction and one-time exceptional charges. The consolidated result was salvaged by associate/joint venture profits, suggesting underlying operational weakness. Despite the loss, the dividend was maintained, signalling management's intent, but the stock is likely to be under pressure given the PAT reversal.